Drugs / BR108
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06018506 | Mar 2023 → May 2024 | hematopoietic and lymphoid system neoplasm | BioRay Pharmaceutical Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06018506 ↗ |
| Route | Intravenous | “Given into the vein (IV; intravenously)” NCT06018506 ↗ |